Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces new data will be presented at the Annual Meeting of the Orthopaedic Research Society in New Orleans, LA, March 10-13, 2018.

This study performed by the research group led by Lawrence Bonassar Ph.D., Professor at the Meinig School of Biomedical Engineering at Cornell University and the scientists from Fidia Farmaceutici examined the relationship between the lubricating properties of HYADD®4, the key component of HYMOVIS®, an HA viscosupplement, and chondrocyte health after sliding articular cartilage in HYADD®4 explanted from neonatal, bovine femoral condyles. The study demonstrated that HYADD®4 lowers friction, tissue surface strains, chondrocyte death and apoptosis in cartilage explants. “This current study is consistent with the idea that hyaluronic acid therapies for arthritis may act in part through a mechanical pathway that preserves viability of chondrocytes at the cartilage surface,” states Dr. Bonassar.*

This new data will be presented at the Annual Meeting of the Orthopaedic Research Society (ORS) on Sunday, March 11, 2018, at the Hyatt Regency New Orleans: (https://www.ors.org/Transactions/64/0444.pdf).

The company reports HYMOVIS® is a highly viscoelastic non-crosslinked hydrogel bioengineered using a proprietary process that increases lubrication and shock absorption properties. This results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints. The formulation allows this unique molecule to recover its original structure, even after repetitive mechanical stress. Due to reversible hydrophobic interactions, the non-crosslinked HYMOVIS® has increased elasticity, viscosity and residence time in the joint.* Its unique molecular structure results in enhanced biomechanical properties and long lasting efficacy, all in a convenient two dose regimen.

*Preclinical studies may not be indicative of human clinical outcomes.

HYMOVIS® is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics. HYMOVIS® is contraindicated in patients with known hypersensitivity to hyaluronate preparations or gram positive bacterial proteins or patients with infections/skin diseases in the area of the injection site/joint. The safety and effectiveness of HYMOVIS® has not been tested in pregnant women, nursing mothers or children. See package insert for full prescribing information including adverse events, warnings, precautions, and side effects at www.hymovis.com.

Rx Only. HYMOVIS® and HYADD®4 are registered trademarks of Fidia Farmaceutici S.p.A., Abano, Terme, Italy. ©2018 Fidia Pharma USA Inc., Florham Park, NJ, a wholly owned subsidiary of Fidia Farmaceutici S.p.A. FID608-02.2018